Nanobiotix half year results for the six months ended 30 June 2017 - Markets Insider

Nanobiotix half year results for the six months ended 30 June 2017 Markets Insider Following the recommendation from the IDMC to continue the phase II/III trial in Soft Tissue Sarcoma, the company has also announced successful clinical results from the Phase I/II Trial of NBTXR3 in Head & Neck Cancer. The private placement completed ... and more »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2emdCDe
via IFTTT